Method for determining content of arachidonic acid metabolic pathway COX-2 metabolite in inflammation model

Through the Agilent 6495 triple quadrupole mass spectrometer and UHPLC-QQQ-MS/MS method, the problem of only a small number of AA metabolites in the prior art was solved, and the rapid, sensitive and stable 11 metabolites in the inflammation model were achieved. Quantitative analysis of good sex is suitable for the determination of COX-2 metabolite content in different inflammation models.

CN119064507AActive Publication Date: 2024-12-03GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411251316.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-07
Publication Date
2024-12-03
Estimated Expiration
2044-09-07

AI Technical Summary

Technical Problem

The prior art can only detect 1-2 metabolites in the arachidonic acid metabolic pathway in the detection inflammation model, and cannot fully understand the overall metabolic status of AA, and there are problems of sample instability and high detection cost.

Method used

The Agilent 6495 triple quadrupole mass spectrometer combined with UHPLC-QQQ-MS/MS method can be used to perform pre-treatment and post-detection of cell supernatant and serum samples, and the content of 11 AA metabolites can be quantitatively analyzed simultaneously, including TXB1 and PGF2β. , TXB2, PGE2, PGE1, PGD1, PGD2, PGA2, PGJ2, PGB2, PGA1, etc.

Benefits of technology

A rapid, sensitive and stable quantitative analysis of 11 metabolites of AA metabolic pathways in the inflammation model was achieved, which reduced the sample number requirement, improved the detection efficiency and information volume, and was suitable for COX-2 metabolites in different inflammation models. Content determination.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119064507A_ABST
    Figure CN119064507A_ABST
Patent Text Reader

Abstract

The invention relates to a method for measuring the content of arachidonic acid metabolic pathway COX-2 metabolites in an inflammation model, which comprises the following steps: (1) sample pretreatment: pretreating a cell supernatant sample and / or a serum sample, and adding an internal standard working solution which is a PGA2-D4 solution in the pretreatment process; and (2) detecting the treated sample by adopting an Agilent 6495 triple quadrupole mass spectrometer. The method provided by the invention can be used for simultaneously detecting the contents of 11 metabolites in the AA metabolic pathway, and has the advantages of rapidness, high sensitivity, good stability and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of detection technology, and in particular relates to a method for determining the content of COX-2 metabolites in an arachidonic acid metabolic pathway in an inflammation model. Background Art

[0002] Arachidonic acid (AA) is a ω-6 polyunsaturated fatty acid and the most widely distributed endogenous active substance in the body. It plays an important role in maintaining the structure and function of the body's cell membranes. AA is not only an essential phospholipid in various tissues and organs of the body, but also an important precursor for the synthesis of prostaglandins (PG) in the human body. In the AA metabolic network, AA produces a series of metabolites such as prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs) or hydroxy fatty acids through three metabolic pathways: cyclooxygenases (COXs), lipoxygenases (LOXs) and cytochrome P450 (CYP450), which trigger different inflammatory responses. Prostaglandins include prostaglandin F 2β (PGF 2β ), prostaglandin E 2 (PGE 2 ), prostaglandin E 1 (PGE 1 ), prostaglandin D 1 (PGD 1 ), prostaglandin D 2 (PGD 2 ), prostaglandin A 1 (PGA 1 ), prostaglandin A 2 (PGA 2 ), prostaglandin J 2 (PGJ 2 ), prostaglandin B 2 (PGB 2 ) etc. Thromboxanes include thromboxane B 1 (TXB 1 ), thromboxane B 2 (TXB 2 ) etc. These AA metabolites are collectively called eicosanoids, which are effective autocrine and paracrine bioactive mediators, important inflammatory factors in the body, participate in the body's immune and inflammatory response processes, and play an important role in the pathophysiological process of many diseases. Inflammation is an important pathological basis of arthritis and a process closely related to the occurrence of arthritis. PGE2 For example, PGE 2 Among the prostaglandins, PGE1 has the strongest effect in promoting bone resorption. 2 receptors, and PGE 2 Combined with PGE 2 Joint histopathology of recipient animals revealed cartilage degradation, loss of proteoglycans, and resulting destruction of type II collagen, which therefore plays an important role in the pathogenesis of arthritis.

[0003] Based on the COX metabolic pathway, there are two subtypes, COX-1 and COX-2. COX-1 is used for basic prostaglandin synthesis and is a constitutive enzyme; COX-2 plays an important role in many inflammations and is produced when stimulated, which is an induced enzyme. The arachidonic acid (AA) metabolic pathway plays an important role in inflammatory responses. However, the overall metabolic profile of AA in inflammatory models remains elusive.

[0004] At present, the detection of inflammatory factors in the AA metabolic pathway still uses enzyme-linked immunosorbent assay, flow cytometry, Western blot and other technologies for single indicator detection, which has problems such as instability of samples from different batches, high detection costs and high requirements for technicians. Pang et al. established a quantitative analysis of PGE2 in the spinal cord tissue of rats at 4h, 24h and 48h after spinal cord contusion. 2and LTB4 (reference: Pang Y, Liu X, Zhao C, et al. LC-MS / MS-based arachidonic acid metabolomics in acute spinal cord injury reveals the upregulation of 5-LOX and COX-2 products. Free Radic Biol Med. 2022; 193(Pt1): 363-372.). Lin et al. established an LC-MS method for determining the content of leukotriene B4 in human plasma samples (reference: LIN W, HUANG MQ, XUE X, et al. A highly sensitive and selective method for the determination of leukotriene B4(LTB4)in ex vivo stimulated human plasma by ultra fast liquid chromatography tandem mass spectrometry[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2013, 925: 54.). Existing methods can only detect the metabolites of 1-2 AA, but the detection of 1-2 AA metabolites cannot clearly understand the overall metabolism of AA in the inflammatory model. Summary of the invention

[0005] In view of the problems existing in the prior art, the present invention provides a method for determining the content of COX-2 metabolites in the arachidonic acid metabolic pathway in an inflammation model. The method provided by the present invention can simultaneously detect the content of 11 metabolites in the AA metabolic pathway, and has the advantages of rapidity, high sensitivity, good stability, etc.

[0006] The technical solution of the present invention to solve the above technical problems is as follows:

[0007] The present invention provides a method for determining the content of COX-2 metabolites in an arachidonic acid metabolic pathway in an inflammation model, comprising the following steps:

[0008] (1) Sample pretreatment: Pre-treat the cell supernatant sample and / or serum sample, and add internal standard working solution during the pre-treatment process. The internal standard working solution is the internal standard substance PGA. 2 -D 4 of solution;

[0009] (2) The treated samples were detected using an Agilent 6495 triple quadrupole mass spectrometer.

[0010] The beneficial effects of adopting the above scheme include: the method provided by the present invention can determine the qualitative and quantitative analysis of components such as AA metabolites and their structural analogs, and expand the application of LC-MS in the detection of PGE 2 The present invention uses the UHPLC-QQQ-MS / MS method to establish a rapid, highly sensitive and stable detection method for 11 metabolites, achieving a large number of samples, a large amount of information and a small amount of single sample required.

[0011] Further, in step (2), the detection conditions include: chromatographic separation on a Waters Acquity UPLC C18 column; the mobile phase is 0.1% formic acid A and acetonitrile B, gradient elution: 40% B for 0-3 minutes, 40%-80% B for 3-8 minutes, and 40% B for 8.01-10 minutes; injection of an equal amount of 5 μL, the FLOW rate is 300 μL / min; the metabolites are detected using MRM and ESI sources in negative ion mode; the drying gas flow rate is 11.0 L / min, the drying gas temperature is 300°C, the nebulizer is 15 psig, and the capillary voltage is 4000V.

[0012] Furthermore, in step (1), the method for pre-treating the cell supernatant sample comprises the following steps: taking 200 μL of the supernatant, adding 50 μL of the internal standard working solution, adding 800 μL of acetonitrile, and vortexing for 3 min; centrifuging at 4°C, 14000 rpm for 10 min, and taking the supernatant; vacuum concentrating; adding 100 μL of chromatographic methanol to re-dissolve, standing and then ultrasonicating, vortexing for 3 min; centrifuging at 4°C, 14000 rpm for 10 min, and taking the supernatant.

[0013] Furthermore, the cell supernatant is the supernatant of the LPS-induced RAW264.7 cell inflammation model.

[0014] Furthermore, in step (1), the method for pre-treating the serum sample comprises the following steps: taking 200 μL of serum, adding 50 μL of internal standard working solution, then adding 800 μL of acetonitrile, and vortexing for 3 min; centrifuging at 4°C, 14000 rpm for 10 min, and taking the supernatant; vacuum concentrating; adding 100 μL of chromatographic methanol to re-dissolve, standing and then ultrasonicating, vortexing for 3 min; centrifuging at 4°C, 14000 rpm for 10 min, and taking the supernatant.

[0015] Furthermore, the serum sample is a serum sample of an adjuvant-induced arthritis (AIA) model or a serum sample of a type II collagen-induced arthritis (CIA) model.

[0016] The beneficial effects of adopting the above scheme include: the present invention uses high performance liquid chromatography tandem mass spectrometry (LC-MS method) to simultaneously perform rapid quantitative analysis of 11 AA metabolites in cell supernatant and animal serum, and has the advantages of rapidity, high efficiency, high sensitivity, good stability, large amount of information, and small amount of single sample required. This method is a suitable method for determining the content of COX-2 metabolites in the construction of various different inflammatory models.

[0017] Furthermore, in step (2), the content of the metabolite is calculated based on the peak area obtained by detection and the standard curve formula.

[0018] When the cell supernatant samples were tested, TXB 1 The standard curve of PGF is y = 0.196x-0.0572. 2β The standard curve of TXB is y = 1.98x-0.0400. 2 The standard curve of PGE is y = 0.928x-0.0335. 2 The standard curve of PGE is y=21.2x-0.259. 1 The standard curve is y = 49.1x-0.500, PGD 1 The standard curve of PGD is y = 4.09x-0.0314. 2 The standard curve of PGA is y = 4.03x-0.232. 2 The standard curve of PGJ is y=48.5x-0.00965. 2 The standard curve of PGB is y=34.8x-0.315. 2 The standard curve of PGA is y = 10.5x-0.0443. 1 The standard curve is y=4.86x-0.0330; in the above, x is the concentration of the target substance in ng / mL, and y is the peak area ratio of the target substance and the internal standard substance.

[0019] When testing serum samples, TXB 1 The standard curve of PGF is y=0.298x+0.0378. 2β The standard curve of TXB is y=12.5x+0.131. 2 The standard curve of PGE is y=8.84x+0.259. 2 The standard curve of PGE is y=110.4x+3.21. 1 The standard curve of PGD is y=243.8x+5.23. 1 The standard curve of PGD is y=76.0x+1.68. 2 The standard curve of PGA is y=646.23X+0.457. 2The standard curve of PGJ is y=6051.63x+0.565. 2 The standard curve of PGB is y=136.94x+14.5. 2 The standard curve of PGA is y=62.8x+1.50. 1 The standard curve is y=24.7x+0.574; in the above, x is the concentration of the target substance in ng / mL, and y is the peak area ratio of the target substance and the internal standard substance.

[0020] Further, in step (1), in the internal standard working solution, PGA 2 -D 4 The concentration is 0.1 μg / mL.

[0021] The beneficial effects of adopting the above scheme include: PGA 2 -D 4 It is more effective as an internal standard, located between the chromatographic peaks of several components being tested and does not overflow, while the other internal standard Arachidonic Acid-d8 was not successfully detected after the sample was re-dissolved. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 These are the experimental results of the LPS-induced RAW264.7 cell inflammation model.

[0023] Figure 2 These are the apparent observation results of rat CIA model and AIA model.

[0024] Figure 3 This is a 3D construction image of Micro-CT, in which (a) the articular surface and bone ends are intact and smooth, the joint space is not widened or narrowed, and there is no abnormality in the surrounding soft tissue; (b) the articular surface bone defect appears, brush-like changes appear, the cartilage edge is irregular, the articular surface is blurred, and the joint space is irregularly narrowed.

[0025] Figure 4 These are the test results for 11 metabolites contained in the mixed reference substance.

[0026] Figure 5 The changes in the content of metabolites in the supernatant of RAW264.7 cells.

[0027] Figure 6 The results of the detection of five metabolites in the supernatant of RAW264.7 cells (bar graph).

[0028] Figure 7 The results of the detection of three metabolites in the serum of AIA model and CIA model rats (bar graph).

[0029] Figure 8Figure 2 shows the changes in the levels of metabolites in the serum of rats with CIA model and AIA model. DETAILED DESCRIPTION

[0030] The principles and features of the present invention are described below in conjunction with the accompanying drawings. The examples given are only used to explain the present invention and are not used to limit the scope of the present invention.

[0031] The present invention selects RAW264.7 macrophage supernatant and serum of SD rat arthritis disease model as research objects, and establishes a rapid, sensitive and reliable LC-MS method to explore the influence of cyclooxygenase pathway in cell and whole animal AA metabolism during inflammation. The present invention selects 11 metabolites produced by arachidonic acid through the COX metabolic pathway, and realizes quantitative detection of 11 inflammatory factors simultaneously in a short time by using less sample (biological sample 200 μL) for simple pretreatment process, which has the advantages of rapidity, high sensitivity and good stability.

[0032] In the present invention, unless otherwise specified, the experimental methods used are conventional experimental methods in the art. The materials, reagents, and instruments used are conventional materials, reagents, and instruments in the art, which can be obtained through commercial channels or prepared by conventional methods.

[0033] TXB 1 (Purity ≥ 98%), PGF 2β (Purity ≥ 98%), TXB 2 (Purity ≥ 98%), PGE 2 (Purity ≥ 98%), PGE 1 (Purity ≥ 98%), PGD 1 (Purity ≥ 98%), PGD 2 (Purity ≥ 98%), PGA 2 (Purity ≥ 98%), PGJ 2 (Purity ≥ 98%), PGB 2 (Purity ≥ 98%), PGA 1 (Purity ≥ 98%), PGA 2 -D 4 Purchased from Cayman Chemical Company.

[0034] Formic acid was purchased from Macklin; acetonitrile and methanol were purchased from ACS.(USA); ultrapure water was purchased from Watsons; DMEM medium was purchased from Gibco, batch number: 8123318; fetal bovine serum was purchased from Gibco; lipopolysaccharide (LPS) was purchased from Sigma; PBS was purchased from Gibco; bovine type II collagen (CII) was purchased from Chondrex; complete Freund's adjuvant was purchased from Chondrex; inactivated Mycobacterium tuberculosis was purchased from BD Company, USA; RAW264.7 cells were purchased from Starfish Biotechnology, catalog number: TCM-C766; SD rats, SPF grade, 180-220g, female, were purchased from Guangdong Province Weitong Lihua Experimental Animal Technology Co., Ltd., license number: SCXK2022-0063.

[0035] The following is an introduction through specific embodiments.

[0036] Example 1 Establishment of LPS-induced RAW264.7 cell inflammation model

[0037] RAW264.7 cells in the logarithmic growth phase were plated in 12-well plates, with 150,000 cells per well, and the drugs were administered after the cells adhered to the wall. A blank group (Blank), an LPS stimulation group (Model group), and a positive drug (dexamethasone DEX) group were set up, with 3 replicates in each group, and 1 mL of culture medium was added to each well. The culture medium (purchased from Gibco, model number C11995500BT) contained D-glucose (4.5 g / L), L-glutamine, sodium pyruvate (110 mg / L) and 10% fetal bovine serum. The final concentration of LPS in the LPS stimulation group was 100 ng / mL, and the final concentration of dexamethasone in the positive drug group was 0.5 μM. One hour after administration, the positive drug group was directly replaced with 1 mL of new culture medium containing positive drug and LPS (i.e., the original culture medium containing only positive drug was replaced with culture medium containing positive drug and LPS, which is equivalent to adding LPS for stimulation one hour after administration of positive drug, with the concentration of positive drug being 0.5 μM and that of LPS being 100 ng / mL). After incubation for 24 hours (the incubation time was calculated from 1 hour after administration), the cell supernatant of each group was collected and PBS (500 μL of PBS was added for infiltration) was added for microscopic photography.

[0038] Microscopic observation results showed that RAW264.7 cells were round in normal state, with smooth cell edges and no pseudopodia, and no vacuoles in the cytoplasm. After 24 hours of LPS stimulation, the surface area of ​​the cells increased, pseudopodia were extended, and the number of vacuoles in the cytoplasm also increased. The administration of positive drugs played a certain protective role against the stimulation of cells. This shows that the LPS-induced RAW264.7 cell inflammation model was successfully constructed ( Figure 1 ).

[0039] Example 2

[0040] 2.1 Experimental methods

[0041] (1) Establishment of rat type II collagen-induced arthritis (CIA) model

[0042] The immunogen was prepared on the day of modeling (day 0), and the preparation process was carried out on a clean bench. In an ice bath environment, equal amounts of bovine type II collagen (CI I) and complete Freund's adjuvant (CFA) were fully mixed at a 1:1 (volume ratio). In the mixed solution, the concentration of bovine type II collagen was 2 mg / mL, and the concentration of CFA was 10 mg / mL. The mixture was stirred and emulsified with a high-speed homogenizer for about 10 minutes, and the final emulsification degree reached a level that it would not disperse when dropped into water, that is, a bovine type II collagen emulsion with a concentration of 1 mg / mL was prepared.

[0043] After one week of adaptive feeding of healthy female SD rats, 12 rats were randomly selected as the blank group (BLANK, the blank group was fed normally without drug injection), and 28 rats were randomly selected as the CIA model group. The CIA group was subcutaneously injected with 0.2 mL of bovine type II collagen emulsion at the right tail root of the rats, and on the 7th day, the same volume (0.2 mL) of bovine type II collagen emulsion as the immunization procedure on day 0 was injected to strengthen the immunization of the rats. On the 14th day, the rat CIA model was established. The blood of the rats was collected and the blood samples were centrifuged at room temperature for 30 minutes to obtain the supernatant, which was the serum.

[0044] The toe volume measuring instrument was used to measure the swelling of the feet of the rats in the above model before and after modeling to determine whether the modeling was successful.

[0045] (2) Establishment of rat adjuvant-induced arthritis (AIA) model

[0046] Ten healthy female SD rats were selected and used for modeling after adaptive feeding for one week. The emulsifier was prepared by weighing 100 mg of inactivated Mycobacterium tuberculosis in a sterile glass mortar and slowly grinding it in the same direction on ice until it turned grayish white. Then, 10 mL of mineral oil was slowly added and continued to grind to mix the two to make a milky white viscous emulsifier. For the first immunization, 0.15 mL of emulsifier was injected into each rat; for booster immunization, 7 days after the first immunization, the above operation was repeated and 0.1 mL of Freund's complete adjuvant was injected into the base of the rat's tail. On the 14th day, the AIA model of rats was completed. The blood of the rats was collected and sampled. The blood samples were allowed to stand at room temperature for 30 minutes and then centrifuged to obtain the supernatant, which was the serum.

[0047] The toe volume measuring instrument was used to measure the swelling of both feet of the rats in the above models before and after modeling to determine whether the modeling was successful.

[0048] 2.2 Experimental Results

[0049] The results of the observation of the CIA and AIA models in rats show that compared with the normal control group (blank group), the redness, swelling, pain, and stiffness of the joints of the rats in the CIA model group and the AIA model group are consistent with the characteristics of active arthritis ( Figure 2 ).

[0050] The results of the 3D construction of the rat CIA model showed that the joint surface and bone ends of the right hind limbs of the rats in the normal group (Control group) were intact and smooth, the joint space was not widened or narrowed, and the surrounding soft tissues were normal; while the right hind limb joint surface of the rats in the CIA model group had bone defects, brush-like changes, irregular cartilage edges, blurred joint surfaces, and irregular narrowing of the joint space, indicating that the rat type II collagen-induced arthritis model was successfully constructed ( Figure 3 ).

[0051] The results of toe volume measurement in rat type II collagen-induced arthritis (CIA) / adjuvant-induced arthritis (AIA) models showed that the toe volumes of rats in each group were measured by toe volume measuring instrument on day 0, day 7, and day 14. Compared with the normal control group (BLANK), the toe volumes of the CIA model group and the AIA model group increased significantly, and increased rapidly after the second booster immunization, with statistically significant differences ( ** P<0.01) (see Table 1).

[0052] Table 1 Measurement of toe volume (cm) in rat arthritis model 3 )

[0053]

[0054] ** P<0.01, vs BLANK group

[0055] Example 3 Methodological Establishment

[0056] 3.1 Experimental methods

[0057] (1) Prepare standard solution

[0058] Weigh TXB accurately 1 、PGF 2β TXB 2 , PGE 2 , PGE 1 PGD 1 PGD 2 、PGA 1 、PGA 2 PGJ 2 , PGB 2An appropriate amount of reference substance was prepared into a single reference substance stock solution with methanol. The concentrations of the stock solutions were 100 μg / mL, 17.8 μg / mL, 18.1 μg / mL, 18.5 μg / mL, 15.7 μg / mL, 20 μg / mL, 112 μg / mL, 12.3 μg / mL, 10 μg / mL, 10 μg / mL, and 10 μg / mL, respectively.

[0059] Then accurately pipette an appropriate amount of the stock solution of each single reference substance to prepare a mixed reference substance. Each 1 mL of the mixed reference substance contains: TXB 1 6.000μg, PGF 2β 1.068μg, TXB 2 0.905μg, PGE 2 1.110μg, PGE 1 0.550μg, PGD 1 0.400 μg, PGD 2 1.120μg, PGA 1 0.369μg, PGA 2 0.100 μg, PGJ 2 0.150μg, PGB 2 0.200μg.

[0060] (2) Prepare internal standard solution

[0061] Take PGA 2 -D 4 Add an appropriate amount of reference substance to methanol to prepare a 0.1 mg / mL stock solution, and store at 4°C. Before use, add methanol to dilute the stock solution to 0.1 μg / mL to obtain the internal standard working solution.

[0062] (3) Pretreatment of cell supernatant samples

[0063] Take 200 μL of the supernatant and add the internal standard working solution (PGA 2 -D 4 Solution) 50 μL, then add 800 μL of acetonitrile, vortex for 3 min; centrifuge at 4°C, 14000 rpm for 10 min, take the supernatant; vacuum concentrate using a nitrogen blower, store at -80°C for later use; add 100 μL of chromatographic methanol, redissolve, let stand, then ultrasonicate, vortex for 3 min; centrifuge at 4°C, 14000 rpm for 10 min, take the supernatant into a sampling bottle.

[0064] (4) Pretreatment of rat serum samples

[0065] Take 200 μL of serum and add the internal standard working solution (PGA 2 -D 4Solution) 50 μL, then add 800 μL of acetonitrile, vortex for 3 min; centrifuge at 4°C, 14000 rpm for 10 min, take the supernatant; vacuum concentrate using a nitrogen blower, store at -80°C for later use; add 100 μL of chromatographic methanol, redissolve, let stand, then ultrasonicate, vortex for 3 min; centrifuge at 4°C, 14000 rpm for 10 min, take the supernatant into a sampling bottle.

[0066] (5) An Agilent 6495 triple quadrupole mass spectrometer (QQQ-MS, Agilent Technologies, Santa Clara, CA, USA) was used in conjunction with the mass spectrometry conditions in Table 2 to quantitatively detect inflammatory factors. Chromatographic separation was performed on a Waters Acquity UPLC C18 column (1.7 μm, 2.1 mm×100 mm, Waters, Milford). The mobile phase was 0.1% formic acid (A) and acetonitrile (B), with a gradient elution of: 40% B for 0-3 minutes, 40%-80% B for 3-8 minutes, and 40% B for 8.01-10 minutes. The above percentages are all volume percentages. An equal amount of 5 μL was injected, and the flow rate (FLOW) was 300 μL / min. Metabolites were detected using MRM and ESI sources in negative ion mode. Other parameters are as follows: Drying gas (N 2 ) flow rate is 11.0 L / min, drying gas temperature is 300°C; atomizer, 15 psig; capillary voltage is 4000 V.

[0067] Table 2 Mass spectrometry conditions

[0068]

[0069] 3.2 Experimental Results

[0070] (1) Specificity of the method

[0071] The following method was used to detect the 11 metabolites in the mixed reference substance: the mixed reference substance was prepared using the method in step (1) of Example 3.1, 200 μL of the mixed reference substance was taken, and the internal standard working solution (PGA 2 -D 4 50 μL of solution) was added, and then 800 μL of acetonitrile was added, and vortexed for 3 minutes; centrifuged at 4°C, 14000 rpm for 10 minutes, and the supernatant was taken; vacuum concentrated using a nitrogen blower, and stored at -80°C for later use; 100 μL of chromatographic methanol was added, and redissolved, allowed to stand, and then ultrasonicated, vortexed for 3 minutes; centrifuged at 4°C, 14000 rpm for 10 minutes, and the supernatant was taken into a sample injection bottle. Afterwards, the 11 metabolites contained in the mixed reference substance prepared were detected using the conditions of (5) in Example 3.1.

[0072] The results showed that the 11 metabolites contained in the tested samples could be completely separated from the internal standard, with symmetrical peaks and no interference from endogenous substances. Figure 4 .

[0073] (2) Standard curve, linear range and minimum quantitative concentration

[0074] Take an appropriate amount of mixed reference substance (e.g., 200 μL). The preparation method of the mixed reference substance refers to Example 3.1(1). The mixed reference substance is treated by the method of Example 3.1(3).

[0075] 200 μL of the blank group culture medium was treated using the method of Example 3.1(3).

[0076] 200 μL of serum from the blank group rats was treated using the method of Example 3.1(4).

[0077] The blank group rat serum refers to the rat serum of the blank control group in Example 2; the blank group culture medium refers to the cell culture medium of the blank control group during cell culture in Example 1 (ie, the pure culture medium for RAW264.7 cell culture).

[0078] The mixed control substance, blank group culture medium and blank group rat serum after the above treatment were tested according to the method (5) in Example 3.1.

[0079] The peak area ratio Y of the target substance and the internal standard was used to perform regression operation on the target concentration X (ng / mL) using the weighted least squares method. The results are shown in Tables 3 and 4. It can be seen from Tables 3 and 4 that r is greater than 0.99, indicating that the linear relationship of the 11 metabolites is good in each range.

[0080] Table 3 Standard curve of blank culture medium

[0081]

[0082]

[0083] Table 4 Standard curve of blank group rat serum

[0084]

[0085] (3) Accuracy, precision, and extraction recovery

[0086] According to Table 5, different concentrations of 11 metabolites were added to the blank culture medium, mixed, and prepared into low, medium, and high concentration blank culture medium samples; 200 μL of the blank culture medium sample was taken and processed according to the method of 3.1(3) as a quality control sample.

[0087] Table 5 Concentrations of 11 substances in the low, medium and high samples of the blank culture medium (ng / mL)

[0088] <![CDATA[TXB 1 ]]> <![CDATA[PGF 2β ]]> <![CDATA[TXB 2 ]]> <![CDATA[PGE 2 ]]> <![CDATA[PGE 1 ]]> <![CDATA[PGD 1 ]]> <![CDATA[PGD 2 ]]> <![CDATA[PGA 2 ]]> <![CDATA[PGJ 2 ]]> <![CDATA[PGB 2 ]]> <![CDATA[PGA 1 ]]> Low 188 16.7 14.1 17.3 8.60 6.30 17.5 0.234 2.30 3.10 5.80 middle 750 66.8 113 69.4 34.3 25.0 70.0 6.30 9.40 12.3 23.1 high 4800 427 724 444 220 160 448 40.0 120 160 148

[0089] According to Table 6, different concentrations of 11 metabolites were added to the blank group rat serum, mixed, and prepared into low, medium, and high concentration blank group rat serum samples; 200 μL of blank group rat serum was taken and processed according to the method of 3.1 (4) as a quality control sample.

[0090] Table 6 Concentrations of 11 substances in the low, medium and high samples of the blank group rat serum (ng / mL)

[0091] <![CDATA[TXB 1 ]]> <![CDATA[PGF 2β ]]> <![CDATA[TXB 2 ]]> <![CDATA[PGE 2 ]]> <![CDATA[PGE 1 ]]> <![CDATA[PGD 1 ]]> <![CDATA[PGD 2 ]]> <![CDATA[PGA 2 ]]> <![CDATA[PGJ 2 ]]> <![CDATA[PGB 2 ]]> <![CDATA[PGA 1 ]]> Low 93.8 33.4 14.1 17.3 8.60 6.30 1.75 0.234 4.60 6.30 11.5 middle 375 134 56.6 139 68.6 50.0 140 12.6 18.8 25.0 46.1 high 2400 854 362 888 440 180 896 80.0 120 160 295

[0092] The extraction recovery of the samples was investigated by comparing the peak area of ​​the chromatogram of the extracted metabolites to the peak area of ​​the chromatogram of the 11 metabolite reference solutions. Three samples were analyzed for each concentration. The extraction recovery of the blank group culture medium samples at three concentrations was in the range of 97.7%-111%, and the RSD range was 0.294%-11.6%. The extraction recovery of the blank group rat serum samples at three concentrations was in the range of 88.4%-108%, and the RSD range was 0.0384-4.74%. Therefore, the extraction recovery was in the range of 85%-115%, which met the requirements. The same method was used to determine the concentration of the samples within 3 days, and the daytime accuracy and precision were calculated. The intra-day precision RSD of blank culture medium samples was between 0.535% and 6.48%, and the inter-day precision RSD was between 0.111% and 10.2%; the intra-day precision RSD of blank group rat serum samples was between 0.225% and 3.95%, and the inter-day precision RSD was between 0.174% and 8.79%. All RSD values ​​were less than 15%. Therefore, the intra-day and inter-day precision and accuracy of this method met the requirements.

[0093] (4) Stability

[0094] Quality control samples: The low, medium and high concentration blank culture medium samples and low, medium and high concentration blank rat serum samples prepared in step (3) above are used as quality control samples. The low, medium and high concentration blank culture medium samples are treated according to the method in 3.1(3), and the low, medium and high concentration blank rat serum samples are treated according to the method in 3.1(4).

[0095] The treated quality control samples were frozen and thawed under the following conditions: (a) room temperature for 6 h, (b) -20 °C for 30 days, (c) repeated freezing and thawing for 3 times;

[0096] The treated samples were tested using method 3.1(5). The results showed that the RSD of the stability of the blank group rat serum samples under the above storage conditions was 0.0161%-5.95%, and the RSD of the stability of the blank group culture medium samples under the above storage conditions was 0.258%-7.39%. The stability RSD values ​​of all samples were less than 10%, so the samples were stable under the above storage conditions.

[0097] Example 4 Detection of changes in inflammatory factors in the LPS-stimulated RAW264.7 macrophage inflammation model

[0098] (1) Take 200 μL of the cell supernatant of the LPS-induced RAW264.7 cell inflammation model and add the internal standard working solution (PGA 2 -D 4 Solution) 50 μL, then add 800 μL of acetonitrile, vortex for 3 min; centrifuge at 4°C, 14000 rpm for 10 min, take the supernatant; vacuum concentrate using a nitrogen blower, store at -80°C for later use; add 100 μL of chromatographic methanol, redissolve, let stand, then ultrasonicate, vortex for 3 min; centrifuge at 4°C, 14000 rpm for 10 min, take the supernatant into a sampling bottle.

[0099] In the above method, the method for constructing the LPS-induced RAW264.7 cell inflammation model is as described in Example 1. The method for preparing the internal standard working solution is as described in Example 3.1(2).

[0100] (2) The method of Example 3.1 (5) was used to detect the contents of 11 metabolites in the model. The peak areas obtained by the detection were substituted into the formula of the standard curve (Table 3). The standard curve formula in Table 3 was obtained by regressing the peak area ratio Y of the target substance and the internal standard substance against the target concentration X (ng / mL) using the weighted least squares method, and the contents of the metabolites were calculated. The detection results of the contents of 5 metabolites are shown in Table 7.

[0101] Table 7 Contents of five metabolites in the supernatant of RAW264.7 cells (ng / mL)

[0102] <![CDATA[PGE 2 ]]> <![CDATA[PGD 1 ]]> <![CDATA[PGD 2 ]]> <![CDATA[PGA 2 ]]> <![CDATA[PGJ 2 ]]> BLANK 0.641±0.0172 0 2.99±0.0461 0 0.241±0.0136 LPS group 2.501±0.277 10.2±0.951 46.7±4.09 0.778±0.0561 21.5±1.90 DEX Group 1.32±0.105 3.67±0.434 17.6±1.52 0.206±0.0554 11.3±1.04

[0103] Eleven metabolites were detected by LC-MS. Figure 5 ), among which 5 metabolites changed significantly ( Figure 6 ), and the contents of other metabolites did not change significantly, indicating that among the 11 metabolites detected simultaneously, PGE 2 PGD 1 PGD 2 、PGA 2 PGJ2 The contents of these five metabolites increased significantly, indicating that the comprehensive expression of these five metabolites can be selected as the detection index for detecting inflammation models.

[0104] According to the LC-MS test results (see Figure 5 and Figure 6 ) found that the inflammatory factor PGE 2 PGD 1 PGD 2 、PGA 2 PGJ 2 The contents of different inflammatory factors increased significantly, indicating that the contents of different inflammatory factors change significantly when an inflammatory response occurs, their effects are also different, and in the arachidonic acid metabolic pathway, multiple metabolites often work together to produce an impact.

[0105] Studies have shown that inflammatory factors produced by activation of RAW264.7 macrophages induced by lipopolysaccharide (LPS) play an important role in the occurrence and development of inflammation and metabolic disorders. As a key proinflammatory enzyme, cytosolic phospholipase A2 (cPLA2) catalyzes the hydrolysis of membrane glycerophospholipids and releases AA. LPS increases cPLA2 in inflammatory cells, thereby producing AA. Under the action of COX, AA can form prostaglandin ring peroxide PGH 2 and PGG 2 These two prostaglandin ring peroxides are very easy to generate PGs, PGH 2 and PGG 2 Both can be converted into PGD under the action of isomerase 2 、PGF 2 , PGE 2 and PGI 2 .

[0106] The results of the LC-MS method established in the present invention showed that PGE 2 PGD 1 PGD 2 、PGA 2 PGJ 2 While the content increased, the positive drug (dexamethasone DEX) could inhibit the expression of cPLA2 and COX-2 in LPS-induced cells. After the positive drug (DEX) was added to the inflammatory cells, PGE 2 、PGA 2 PGD 2 and PGJ 2 The levels of inflammatory factors such as PGD were downregulated. 2 and its metabolite PGJ 2 At different stages of inflammation, arachidonic acid is converted into different prostaglandins, from PGE2 PGD ​​to Remission 2 This change is regulated by microsomal prostaglandin E synthase-1, which is only increased during the acute phase of inflammation (when the product of COX-2 is PGE 2 The synthase then disappears, accompanied by PGD 2 The increase in the content of PGD indicates that the inflammation begins to subside. 2 and PGJ 2 The obvious increase in the level of PGE indicates that the inflammation has entered the stage of resolution. Therefore, it is also suggested that when detecting the inflammatory indicators of LPS-induced inflammatory cells, in order to better explain the stage of inflammation, only PGE 2 A single indicator is not comprehensive enough, and PGD should be added as anterior and posterior 2 and PGJ 2 , the comprehensive expression of multiple indicators is more convincing.

[0107] Example 5 Detection of changes in inflammatory factors in rat arthritis model

[0108] (1) Take 200 μL of serum and add internal standard working solution (PGA 2 -D 4 Solution) 50 μL, then add 800 μL of acetonitrile, vortex for 3 min; centrifuge at 4°C, 14000 rpm for 10 min, take the supernatant; vacuum concentrate using a nitrogen blower, store at -80°C for later use; add 100 μL of chromatographic methanol, redissolve, let stand, then ultrasonicate, vortex for 3 min; centrifuge at 4°C, 14000 rpm for 10 min, take the supernatant into a sampling bottle.

[0109] The serum in the above method is serum of CIA model or AIA model, and the construction methods of CIA model and AIA model refer to Example 2. The preparation method of internal standard working solution refers to Example 3.1(2).

[0110] (2) The method of Example 3.1 (5) was used to detect the contents of 11 metabolites in the model. The peak areas obtained by the detection were substituted into the formula of the standard curve (Table 4). The formula of the standard curve in Table 4 was obtained by regressing the peak area ratio Y of the target substance and the internal standard substance against the target concentration X (ng / mL) using the weighted least squares method to calculate the contents of the metabolites. The results of the content detection of 3 metabolites are shown in Table 8.

[0111] Table 8 Contents of three metabolites in rat serum (ng / mL)

[0112] <![CDATA[PGE 2 ]]> <![CDATA[PGD 2 ]]> <![CDATA[PGA 2 ]]> BLANK 24.3±14.3 1.23±0.137 0.0522±0.00413 AIA 201±72.3 6.78±3.47 0.345±0.137 CIA 45.3±10.4 2.22±0.486 0.0382±0.0216

[0113] The experimental results show that: for the CIA model, there is no significant change in the 11 metabolites, indicating that although the CIA model was successfully established, its model establishment mechanism is different from that of AIA, and the selection of detection indicators is also different from that of AIA. Therefore, these 11 metabolites are not suitable for reflecting the changes in the indicators of the CIA model. 2 PGD 2 、PGA 2 These three metabolites change significantly, so these three metabolites can be selected for comprehensive evaluation in the evaluation of detection indicators for establishing the AIA model.

[0114] According to the LC-MS test results, PGE 2 and its metabolite PGD 2 、PGA 2 The contents of Figure 7 ), while the levels of inflammatory factors in the serum of animals in the CIA model did not change significantly ( Figure 8 ). This experiment used collagen-induced arthritis (CIA) and adjuvant-induced arthritis (AIA) rats as models. The two models simulate different causes. The CIA model is a mixture of type II collagen and complete Freund's adjuvant (in the emulsion, the volume ratio of bovine type II collagen to complete Freund's adjuvant is 1:1) injected twice at the base of the tail. The animals mainly show joint swelling, mainly involving the ankle joint, tarsal joint and interphalangeal joint, and eventually lead to joint deformity. The AIA model is constructed by injecting complete Freund's adjuvant subcutaneously once at the base of the tail. A protein molecule of Mycobacterium tuberculosis is similar in structure to a glycoprotein molecule on the synovial membrane of the joint, and can be recognized by the same strain of T cell clones, thereby inducing an immune response against the joint. This model has obvious cellular immune abnormalities. The AIA model is used to study immune inflammatory models caused by external factors, while the CIA model is suitable for treatment mechanisms and immune-related studies. At the same time, the test results show that the AIA model is more suitable for the method established by the present invention to analyze PGE in AA metabolism than the CI A model. 2 PGD 2 、PGA 2 The content of these three indicators is tested.

[0115] Studies have shown that PGE 2 Participates in joint inflammation, participates in the synthesis of matrix metalloproteinases and induces cartilage degradation, PGE 2 Upregulation accelerates the development of arthritis. TXA 2It is a prostaglandin synthesized and released by platelets that can promote platelet aggregation and cause strong vasoconstriction. AA in platelets synthesizes intermediates through COX-1 or COX-2, which then catalyzes TXA 2 Synthetase synthesizes TXA 2 TXA 2 Extremely unstable, decomposes into inactive TXB in water 2 The basic pathological manifestations of rheumatoid arthritis are synovial hyperplasia and pannus formation in joints. Neovascularization is an important component of pannus. Studies have shown that COX-2 plays a key role in the formation of synovial neovascularization. The catalytic product of COX-2, PGE 2 、PGF 2 TXA 2 etc. can directly or indirectly promote angiogenesis. 2 It can regulate the expression of vascular endothelial growth factor, and its metabolites induce the synthesis of angiogenic factors and promote the formation of new blood vessels. 2 PGD 2 、PGA 2 The content detection method of multiple indicators can more comprehensively explain the occurrence and development of inflammation in the animal AIA model.

[0116] Comparative Example 1

[0117] The proportion of the mobile phase in Example 3.1 (5) was screened. On the basis of Example 3.1 (5), the mobile phases were set as follows. Except for the mobile phase, everything else was the same as Example 3.1 (5).

[0118] Group 1: 10%-90% B for 0-10 minutes;

[0119] Group 2: 25%-90% B for 0-8 minutes, 90% B for 8-10 minutes;

[0120] Group 3: 30% B for 0-10 minutes, 30%-90% B for 10-12 minutes;

[0121] Group 4: 50% B for 0-8 minutes, 50%-90% B for 8-10 minutes, and 90% B for 10-12 minutes;

[0122] Group 5: 45% B for 0-8 minutes, 45%-90% B for 8-10 minutes;

[0123] Group 6: 40% B for 0-8 minutes, 40%-90% B for 8-10 minutes;

[0124] Group 7: 40% B for 0-4 minutes, 40%-60% B for 4-8 minutes;

[0125] Group 8: 35%-40% B for 0-4 minutes, 40%-80% B for 4-8 minutes;

[0126] Group 9: 40% B for 0-3 minutes, 40%-80% B for 3-8 minutes, 40% B for 8.01-10 minutes (ie, the mobile phase used in Example 3.1).

[0127] Take 200 μL of the mixed reference substance, the preparation method of the mixed reference substance is referred to Example 3.1 (1), and the mixed reference substance is treated by the method of Example 3.1 (3). The mixed reference substance is detected using the conditions of the above groups respectively. The experimental results show that the mobile phase conditions used in the present invention (i.e., Group 9) have the advantage of complete separation, while Groups 1 to 8 have problems such as incomplete separation and superposition of isomers.

[0128] Comparative Example 2

[0129] The internal standard working solution (PGA) in (3) of Example 3.1 was 2 -D 4 The blank group culture medium was detected by the above method. The results showed that after using Arachidonic Acid-d8 as the internal standard for detection, 200 μL of supernatant was taken and then 100 μL of methanol was added for re-dissolution. The detection effect was not good. The above results show that the selection of internal standard is crucial to the detection method of the present invention. The internal standard PGA selected by the present invention is 2 -D 4 The invention is a method for detecting 11 metabolites in cell supernatant samples.

[0130] Comparative Example 3

[0131] The internal standard working solution (PGA) in (4) of Example 3.1 was 2 -D 4 Solution) was replaced with an equal amount of Arachidonic Acid-d8 of equal concentration, and the rest was the same as in Example 3.1 (4). The above method was used to detect the serum samples of rats in the blank group. The results showed that after using Arachidonic Acid-d8 as the internal standard for detection, 200 μL of supernatant was taken and finally 100 μL of methanol was added for re-dissolution. The detection effect was not good. The above results show that the selection of the internal standard is crucial to the detection method of the present invention. The internal standard PGA selected by the present invention is 2 -D 4 The invention is a method for detecting 11 metabolites in rat serum samples.

[0132] In summary, the present invention successfully established a method for simultaneously determining TXB 1 、PGF 2β TXB 2 , PGE 2 , PGE 1 PGD 1 PGD 2 、PGA 2 PGJ 2 , PGB 2 、PGA 1 A LC-MS method for rapid quantification of 11 inflammatory factors, including inflammatory factors, was developed, and its advantages of rapidity, sensitivity and accuracy were verified. Traditional detection methods are difficult to achieve accurate quantitative detection of multiple inflammatory indicators at the same time, but the method provided by the present invention can quickly and accurately obtain the concentration of the substance to be tested in an unknown biological sample within a wider detection range, with higher specificity and accuracy. The established method was successfully applied to the analysis of changes in relevant inflammatory factors in biological samples. The results showed that the analyzed metabolites had obvious differences in trends and contents, which provided more information for the study of metabolic pathways in the construction of inflammatory models. In addition, the method provided in the present invention can be applied to the method of detecting inflammatory indicators in metabolic pathways constructed in various different inflammatory models.

[0133] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for determining the content of COX-2 metabolites in the arachidonic acid metabolic pathway in an inflammation model, characterized in that: The following steps are involved: (1) Pretreatment of samples: Pretreatment of cell supernatant samples and / or serum samples, adding internal standard working solution during the pretreatment process, wherein the internal standard working solution is a solution of internal standard substance PGA2-D4; (2) The treated samples were detected using an Agilent 6495 triple quadrupole mass spectrometer.

2. The method according to claim 1, characterized in that: In step (2), the detection conditions include: chromatographic separation on a WatersAcquity UPLC C18 column; the mobile phase is 0.1% formic acid A and acetonitrile B, gradient elution: 40% B for 0-3 minutes, 40%-80% B for 3-8 minutes, and 40% B for 8.01-10 minutes; injection of an equal amount of 5 μL, a FLOW rate of 300 μL / min; metabolites are detected using MRM and ESI sources in negative ion mode; the drying gas flow rate is 11.0 L / min, the drying gas temperature is 300°C, the nebulizer is 15 psig, and the capillary voltage is 4000V.

3. The method according to claim 1 or 2, characterized in that: In step (1), the method for pre-treating the cell supernatant sample comprises the following steps: taking 200 μL of the supernatant, adding 50 μL of the internal standard working solution, adding 800 μL of acetonitrile, and vortexing for 3 min; centrifuging at 4°C, 14000 rpm for 10 min, and taking the supernatant; vacuum concentrating; adding 100 μL of chromatographic methanol to re-dissolve, standing and then ultrasonicating, vortexing for 3 min; centrifuging at 4°C, 14000 rpm for 10 min, and taking the supernatant.

4. The method according to claim 3, characterized in that: The cell supernatant is the supernatant of the LPS-induced RAW264.7 cell inflammation model.

5. The method according to claim 1 or 2, characterized in that: In step (1), take 200 μL of serum, add 50 μL of internal standard working solution, add 800 μL of acetonitrile, and vortex for 3 min; centrifuge at 4°C, 14000 rpm for 10 min, and take the supernatant; vacuum concentrate; add 100 μL of chromatographic methanol to re-dissolve, let stand, then sonicate, vortex for 3 min; centrifuge at 4°C, 14000 rpm for 10 min, and take the supernatant.

6. The method according to claim 5, characterized in that: The serum samples are serum samples of adjuvant-induced arthritis model or serum samples of type II collagen-induced arthritis model.

7. The method according to claim 1 or 2, characterized in that: In step (2), the content of the metabolite is calculated based on the peak area obtained by detection and the standard curve formula.

8. The method according to claim 7, characterized in that: When the cell supernatant samples were tested, the standard curve of TXB1 was y=0.196x-0.0572, PGF 2β The standard curve of is y=1.98x-0.0400, the standard curve of TXB2 is y=0.928x-0.0335, the standard curve of PGE2 is y=21.2x-0.259, the standard curve of PGE1 is y=49.1x-0.500, the standard curve of PGD1 is y=4.09x-0.0314, the standard curve of PGD2 is y=4.03x-0.232, the standard curve of PGA2 is y=48.5x-0.00965, the standard curve of PGJ2 is y=34.8x-0.315, the standard curve of PGB2 is y=10.5x-0.0443, and the standard curve of PGA1 is y=4.86x-0.0330; in the above, x is the concentration of the target, the unit is ng / mL, and y is the peak area ratio of the target and the internal standard.

9. The method according to claim 7, characterized in that: When testing serum samples, the standard curve of TXB1 is y=0.298x+0.0378, PGF 2β The standard curve of is y=12.5x+0.131, the standard curve of TXB2 is y=8.84x+0.259, the standard curve of PGE2 is y=110.4x+3.21, the standard curve of PGE1 is y=243.8x+5.23, the standard curve of PGD1 is y=76.0x+1.68, the standard curve of PGD2 is y=646.23X+0.457, the standard curve of PGA2 is y=6051.63x+0.565, the standard curve of PGJ2 is y=136.94x+14.5, the standard curve of PGB2 is y=62.8x+1.50, and the standard curve of PGA1 is y=24.7x+0.574; in the above, x is the concentration of the target in ng / mL, and y is the peak area ratio of the target and the internal standard.

10. The method according to claim 1 or 2, characterized in that: The concentration of PGA2-D4 in the internal standard working solution was 0.1 μg / mL.

Citation Information

Patent Citations

  • Method for detecting arachidonic acid-like substances

    CN110531007A

  • Compositions and methods for detecting and quantifying COX-2 activity and 2-arachidonylglycerol metabolites

    US20020064804A1

  • Process for extracting the alkaloid fraction of rhodophiala bifida (herb.) traub and uses thereof

    US20160024074A1